MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jaut.2025.103420

Медицинская библиотека · Journal of autoimmunity · 2025

Treatment of mixed connective tissue disease: A multicenter retrospective study.

Chevalier Kevin, Thoreau Benjamin, Michel Marc, Godeau Bertrand, Agard Christian, Papo Thomas, Sacre Karim, Seror Raphaèle, Mariette Xavier, Cacoub Patrice, Benhamou Ygal, Levesque Hervé, Goujard Cécile, Lambotte Olivier, Bonnotte Bernard, Samson Maxime, Ackermann Félix, Schmidt Jean, Duhaut Pierre, Jean-Emmanuel Kahn, Hanslik Thomas, Costedoat-Chalumeau Nathalie, Terrier Benjamin, Regent Alexis, Dunogue Bertrand, Cohen Pascal, Guern Véronique LE, Hachulla Eric, Chaigne Benjamin, Mouthon Luc

СтатьяМногоцентровое исследованиеНаблюдательное исследованиеПеревод в очереди

Аннотация

INTRODUCTION

Mixed connective tissue disease (MCTD) is a rare systemic disorder that belongs to connective tissue diseases (CTD). Few studies are available on MCTD treatment.

METHODS

We conducted an observational study within the French MCTD cohort. Data were collected at diagnosis, during follow-up, and at the last follow-up (LFU). We studied three treatment groups i) no treatment, ii) hydroxychloroquine (HCQ) and/or glucocorticoids (GC) and iii) disease-modifying antirheumatic drugs (DMARDs)/immunosuppressant (IS).

RESULTS

Three hundred and fifteen patients were included and followed for 96 [40-156] months. At MCTD diagnosis, 52 (16.5 %) patients were treatment-free, while 224 (71.1 %) received GC and/or HCQ and 39 (12.4 %) received DMARDs and/or IS. During follow-up, 10 (3.2 %) patients remained treatment-free, and 77 (24.4 %) were GC-free. Most patients (n = 271; 85.8 %) received HCQ, and 161 (51.1 %) were treated with DMARDs and/or IS. DMARDs and/or IS, including anti-B cell therapeutics, were more frequently prescribed in patients with musculoskeletal involvement (p < 0.0001), interstitial lung disease (ILD, p < 0.0001) and/or pulmonary arterial hypertension (PAH, p < 0.01). Patients in clinical remission and those who did not evolve to a differentiated CTD (MCTD-dCTD) received significantly less frequently DMARDs and/or IS (including anti-B cell therapeutics; p < 0.0001 for both). Patients who received HCQ at MCTD diagnosis appeared to develop less frequently ILD or PAH (p < 0.05).

CONCLUSION

HCQ and GC were the cornerstones of MCTD treatment and were sufficient to control disease manifestations in nearly half of the patients, reflecting the good prognosis of this disease. DMARDs and IS were used for musculoskeletal involvement, PAH/ILD, and in MCTD-dCTD patients.

Для цитирования: Chevalier Kevin, Thoreau Benjamin, Michel Marc, Godeau Bertrand, Agard Christian, Papo Thomas, Sacre Karim, Seror Raphaèle, Mariette Xavier, Cacoub Patrice, Benhamou Ygal, Levesque Hervé, Goujard Cécile, Lambotte Olivier, Bonnotte Bernard, Samson Maxime, Ackermann Félix, Schmidt Jean, Duhaut Pierre, Jean-Emmanuel Kahn, Hanslik Thomas, Costedoat-Chalumeau Nathalie, Terrier Benjamin, Regent Alexis, Dunogue Bertrand, Cohen Pascal, Guern Véronique LE, Hachulla Eric, Chaigne Benjamin, Mouthon Luc. Treatment of mixed connective tissue disease: A multicenter retrospective study.. Journal of autoimmunity. 2025. DOI: 10.1016/j.jaut.2025.103420.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.